药物的位点特异性传递，尤其是抗癌药物的位点特异性传递一直是研究人员感兴趣的领域，原因在于细胞毒性药物在癌细胞中积累较低。尽管组合癌症治疗在提供癌症药物敏感性方面非常有益，但药物的位点特异性传递似乎更加高效。在抗癌药物传递中，一种安全、生物相容性和高效的纳米级传递系统是脂质体。它们的粒子大小小，具有可调节的理化性质、易于功能化和高的封装效率等特点。顺铂是一种具有患者临床批准的化疗药物，但由于缺乏特异性传递，其在癌细胞中的积累较低，且反复给药会导致耐药性的发展。基因和药物联合给药，以及与顺铂/紫杉醇联用，已增加肿瘤细胞的敏感性，但在癌症治疗方面还有进一步的空间。脂质体传递顺铂/紫杉醇可以增加药物在肿瘤细胞中的积累，并抑制外排泵活性，促进细胞毒性。此外，光疗与顺铂/紫杉醇传递联合使用可以增加肿瘤抑制的潜力。包括pH敏感性纳米颗粒在内的智能纳米颗粒可以提供对顺铂/紫杉醇的位点特异性传递。通过利用配体对脂质体进行功能化，可以增加其对肿瘤细胞的靶向性，介导对顺铂/紫杉醇的位点特异性传递。最后，脂质体可以介导顺铂/紫杉醇与药物或基因的共传递，增强肿瘤抑制作用。由于药物耐药性导致癌症患者治疗失败的情况，顺铂/紫杉醇是广泛使用的化疗药物之一，这些药物的传递介导了癌症的靶向抑制，并预防了药物耐药性的发展。由于脂质体具有生物相容性和安全性，目前已在癌症患者的临床试验中使用。未来需要确定在临床试验中使用脂质体的最佳剂量以及最佳顺铂/紫杉醇负载浓度。版权所有 © 2023。由Elsevier公司出版。

The site-specific delivery of drugs, especially anti-cancer drugs has been an interesting field for researchers and the reason is low accumulation of cytotoxic drugs in cancer cells. Although combination cancer therapy has been beneficial in providing cancer drug sensitivity, targeted delivery of drugs appears to be more efficient. One of the safe, biocompatible and efficient nano-scale delivery systems in anti-cancer drug delivery is liposomes. Their particle size is small and they have other properties such as adjustable physico-chemical properties, ease of functionalization and high entrapment efficiency. Cisplatin is a chemotherapy drug with clinical approval in patients, but its accumulation in cancer cells is low due to lack of targeted delivery and repeated administration results in resistance development. Gene and drug co-administration along with cisplatin/paclitaxel have resulted in increased sensitivity in tumor cells, but there is still space for more progress in cancer therapy. The delivery of cisplatin/paclitaxel by liposomes increases accumulation of drug in tumor cells and impairs activity of efflux pumps in promoting cytotoxicity. Moreover, phototherapy along with cisplatin/paclitaxel delivery can increase potential in tumor suppression. Smart nanoparticles including pH-sensitive nanoparticles provide site-specific delivery of cisplatin/paclitaxel. The functionalization of liposomes can be performed by ligands to increase targetability towards tumor cells in mediating site-specific delivery of cisplatin/paclitaxel. Finally, liposomes can mediate co-delivery of cisplatin/paclitaxel with drugs or genes in potentiating tumor suppression. Since drug resistance has caused therapy failure in cancer patients, and cisplatin/paclitaxel are among popular chemotherapy drugs, delivery of these drugs mediates targeted suppression of cancers and prevents development of drug resistance. Because of biocompatibility and safety of liposomes, they are currently used in clinical trials for treatment of cancer patients. In future, the optimal dose of using liposomes and optimal concentration of loading cisplatin/paclitaxel on liposomal nanocarriers in clinical trials should be determined.Copyright © 2023. Published by Elsevier Inc.